Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of COVID-HIG in Healthy Adults
NCT05142306Phase 1Completed
- Sponsor
- Emergent BioSolutions
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anti-COVID-19 immune globulin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Emergent BioSolutions. Primary endpoints: Participants With Adverse Events at 72 hours, Participants With Adverse Events That Led to Discontinuation or Temporary Suspension of Study Treatment at Day 1 and 7 more. Started Dec 2021; status: completed.
02
Drugs
anti-COVID-19 immune globulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05142306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142306.